PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo

Cancer Biology and Therapy

Volumn 4, Issue 8, 2005, Pages 874-882

  Tian, Fang ^a,b   Zhang, Xiongwen ^a   Tong, Yunguang ^a,b   Yi, Yanghua ^c   Zhang, Shilong ^c   Li, Ling ^c   Sun, Peng ^c   Lin, Liping ^a   Ding, Jian ^a,d  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Angiogenesis; Anti tumor; Apoptosis; Endothelial cells; Marine; PE; VEGFR2

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PAXILLIN; PROTEIN KINASE B; SAPONIN DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; 3 (3 O METHYLGLUCOPYRANOSYL 1 3 XYLOPYRANOSYL 1 4 (6 DEOXYGLUCOPYRANOSYL) 1 2 (4 SULFOXYLOPYRANOSYL)) 25 CHLORO 25,26 DIHYDRO 20 HYDROXY 27 DEMETHYL 4,4,14 TRIMETHYLCHOLEST 7 ENE 18 OIC ACID 18 20 LACTONE; 3-(3-O-METHYLGLUCOPYRANOSYL-1-3-XYLOPYRANOSYL-1-4-(6-DEOXYGLUCOPYRANOSYL)-1-2-(4-SULFOXYLOPYRANOSYL))-25-CHLORO-25,26-DIHYDRO-20-HYDROXY-27-DEMETHYL-4,4,14-TRIMETHYLCHOLEST-7-ENE-18-OIC ACID 18-20 LACTONE; SAPONIN; TYROSINE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ECHINODERM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PENTACTA QUADRANGULARIS; SARCOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; BIOASSAY; CELL LINE; CHEMISTRY; CHICK EMBRYO; CHORIOALLANTOIS; DRUG ANTAGONISM; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION; SEA CUCUMBER; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL ASSAY; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; SAPONINS; SEA CUCUMBERS; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 25144483915     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.8.1917     Document Type: Article

References (28)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
2. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6:1005-24.
3. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90:1-7.
4. Deplanque G, Harris AL. Anti-angiogenic agents: Clinical trial design and therapies in development. Eur J Cancer 2000; 36:1713-24.
5. Cattley RC, Radinsky RR. Cancer therapeutics: Understanding the mechanism of action. Toxicol Pathol 2004; 32:116-21.
6. Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist 2005; 10:92-103.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
8. Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug Discov Today 2003; 8:536-44.
9. Newman DJ, Cragg GM. Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem 2004; 11:1693-713.
10. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988; 107:1589-98.
11. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12.
12. Soeda S, Kozako T, Iwata K, Shimeno H. Oversulfated fucoidan inhibits the basic fibroblast growth factor- induced tube formation by human umbilical vein endothelial cells: Its possible mechanism of action. Biochim Biophys Acta 2000; 1497:127-34.
13. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem 1997; 272:15442-51.
14. Tan DC, Kini RM, Jois SD, Lim DK, Xin L, Ge R. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 2001; 494:150-6.
15. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. J Cell Sci 2003; 116:3479-89.
16. Gu J, Fujibayashi A, Yamada KM, Sekiguchi K. Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt-and MEK1/ERK-dependent pathways. J Biol Chem 2002; 277:19922-8.
17. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003; 9:1144-55.
18. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13:159-67.
19. Giancotti FG, Tarone G. Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 2003; 19:173-206.
20. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8:17-23.
21. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86.
22. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54:4233-7.
23. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-8.
24. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49:568-81.
25. Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2002; 2:403-14.
26. Sun L, McMahon G. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov Today 2000; 5:344-53.
27. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge Jr GW. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61:3369-72.
28. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. APMIS 2003; 111:995-1003.